Complexity of the chemokine network;Les chimiokines: Un réseau sophistiqué de guidage cellulaire

Medecine/Sciences

Volumn 23, Issue 2, 2007, Pages 173-179

  Combadière, Béhazine ^a   Combadière, Christophe ^a   Deterre, Philippe ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; CHEMOKINE; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CCR9; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR5; GLYCOSAMINOGLYCAN; PROTEINASE; STROMAL CELL DERIVED FACTOR 1; VACCINE;

BONE MARROW; CELL ACTIVATION; CELL INTERACTION; CELL MATURATION; CELL MIGRATION; CELL MOTILITY; CELL TYPE; CIRCULATION; DNA POLYMORPHISM; DRUG UTILIZATION; HUMAN; IMMUNE SYSTEM; LYMPHOID ORGAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; THYMUS;

EID: 33847137657     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/2007232173     Document Type: Review

References (58)

1. Foussat A, Galanaud P, Emilie D. Les chimiokines et la longue marche des leucocytes. Med Sci (Parts) 2000 ; 16 : 757-66.
2. Cyster JG. Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Annu Rev Immunol 2005 ; 23 : 127-59.
3. Mantovani A. The chemokine system: redundancy for robust outputs. Immunol Today 1999 ; 20 : 254-7.
4. Morange M. Déconstruction de la notion de gène. Med Sci (Paris) 2004 ; 20 : 835-6.
5. Luster AD, Alon R, von Andrian UH. Immune cell migration in inflammation: present and future therapeutic targets. Nat Immunol 2005 ; 6 : 1182-90.
6. Rot A, Von Andrian UH. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Ann Rev Imm. 2004 ; 22 : 891-928.
7. Springael JV, Urizar E, Parmentier M. Dimerization of chemokine receptors and its functional consequences. Cytokine Growth Factor Rev 2005 ; 16 : 611-23.
8. Bulenger S, Marullo S, Bouvier M. Emerging role of homo- and heterodimerization in G-protein-coupled receptor biosynthesis and maturation. Trends Pharmacol Sci 2005 ; 26 : 131-7.
9. Jordan BA, Devi LA. G-protein-coupled receptor heterodimerization modulates receptor function. Nature 1999 ; 399 : 697-700.
10. Percherancier Y, Berchiche YA, Slight I, et al. Bioluminescence resonance energy transfer reveals ligand-induced conformational changes in CXCR4 homo- and heterodimers. J Biol Chem 2005 ; 280 : 9895-903.
11. El-Asmar L, Springael JY, Ballet S, et al. Evidence for negative binding cooperativity within CCR5-CCR2b heterodimers. Mol Pharmacol 2005 ; 67 : 460-9.
12. Chen C, Li J, Bot G, et al. Heterodimerization and cross-desensitization between the [mu]-opioid receptor and the chemokine CCR5 receptor. Eur J Pharmacol 2004 ; 483 : 175-86.
13. Lortat-Jacob H, Grosdidier A, Imberty A. Structural diversity of heparan sulfate binding domains in chemokines. Proc Natl Acad Sci USA 2002 ; 99 : 1229-34.
14. Proudfoot AE, Handel TM, Johnson Z, et al. Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc Natl Acad Sci USA 2003 ; 100 : 1885-90.
15. Van Den Steen PE, Wuyts A, Husson SJ, et al. Gelatinase B/MMP-9 and neutrophil collagenase/MMP-8 process the chemokines human GCP-2/CXCL6, ENA-78/CXCL5 and mouse GCP-2/LIX and modulate their physiological activities. Eur J Biochem 2003 ; 270 : 3739-49.
16. Thelen M. Dancing to the tune of chemokines. Nat Immunol 2001 ; 2 : 129-34.
17. Roscic-Mrkic B, Fischer M, Leemann C, et al. RANTES (CCL5) utilizes the proteoglycan CD44 as an auxiliary receptor to mediate cellular activation signals and HIV-1 enhancement. Blood 2003 ; 24 : 24.
18. Moatti D, Faure S, Fumeron F, et al. Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood 2001 ; 97 : 1925-8.
19. Lavergne E, Labreuche J, Daoudi M, et al. Adverse associations between CX3CR1 polymorphisms and risk of cardiovascular or cerebrovascular disease. Arterioscler Thromb Vasc Biol 2005 ; 25 : 847-53.
20. Campbell DJ, Kim CH, Butcher EC. Chemokines in the systemic organization of immunity. Immunol Rev 2003 ; 195 : 58-71
21. Muller G, Hopken UE, Lipp M. The impact of CCR7 and CXCR5 on lymphoid organ development and systemic immunity. Immunol Rev 2003 ; 195 : 117-35.
22. Breitfeld D, Ohl L, Kremmer E, et al. Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. J Exp Med 2000 ; 192 : 1545-52.
23. O'Garra A, McEvoy LM, Zlotnik A. T-cell subsets: chemokine receptors guide the way. Curr Biol 1998 ; 8 : R646-9.
24. Rabin RL, Park MK, Liao F, et al. Chemokine receptor responses on T cells are achieved through regulation of both receptor expression and signaling. J Immunol 1999 ; 162 : 3840-50.
25. Morris MA, Ley K. Trafficking of natural killer cells. Curr Mol Med 2004 ; 4 : 431-8.
26. + monocytes in response to fractalkine under constitutive and inflammatory conditions. Immunobiology 2004 ; 209 : 11-20.
27. Caux C, Vanbervliet B, Massacrier C, et al. Regulation of dendritic cell recruitment by chemokines. Transplantation 2002 ; 73 : S7-11.
28. Murphy PM. Viral exploitation and subversion of the immune system through chemokine mimicry. Nat Immunol 2001 ; 2 : 116-22.
29. Hatabu T, Kawazu S, Aikawa M, et al. Binding of Plasmodium falciparum-infected erythrocytes to the membrane-bound form of Fractalkine/CX3CL1. Proc Natl Acad Sci USA 2003 ; 100 : 15942-6.
30. Onuffer J, Horuk R. Chemokines, chemokine receptors and small-molecule antagonists : recent developments. Trends Pharmacol Sci 2002 ; 23 : 459.
31. Reape TJ, Groot PH. Chemokines and atherosclerosis. Atherosclerosis 1999 ; 147 : 213-25.
32. Bursill CA, Channon KM, Greaves DR. The role of chemokines in atherosclerosis: recent evidence from experimental models and population genetics. Curr Opin Lipidol 2004 ; 15 : 145-9.
33. Eisner J, Escher SE, Forssmann U. Chemokine receptor antagonists: a novel therapeutic approach in allergic diseases. Allergy 2004 ; 59 : 1243-58.
34. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006 ; 354 : 610-21.
35. Hancock WW, Lu B, Gao W, et al. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J Exp Med 2000 ; 192 : 1515-20.
36. Haskell CA, Hancock WW, Salant DJ, et al. Targeted deletion of CX(3)CR1 reveals a role for fractalkine in cardiac allograft rejection. J Clin Invest 2001 ; 108 : 679-88.
37. Gao W, Topham PS, King JA, et al. Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection. J Clin Invest 2000 ; 105 : 35-44.
38. Gao W, Faia KL, Csizmadia V, et al. Beneficial effects of targeting CCR5 in allograft recipients. Transplantation 2001 ; 72 : 1199-205.
39. Hancock WW, Wang L, Ye Q, et al. Chemokines and their receptors as markers of allograft rejection and targets for immunosuppression. Curr Opin Immunol 2003 ; 15 : 479-86.
40. Fischereder M, Luckow B, Hocher B, et al. CC chemokine receptor 5 and renal-transplant survival. Lancet 2001 ; 357 : 1758-61.
41. Sgadari C, Angiolillo AL, Tosato G. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood 1996 ; 87 : 3877-82.
42. Salcedo R, and Oppenheim JJ. Role of chemokines in angiogenesis: CXCL12/SDF-1 and CXCR4 interaction, a key regulator of endothelial cell responses. Microcirculation 2003 ; 10 : 359-70.
43. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004 ; 4 : 540-50.
44. Moran CJ, Arenberg DA, Huang CC, et al. RANTES expression is a predictor of survival in stage I lung adenocarcinoma. Clin Cancer Res 2002 ; 8 : 3803-12.
45. Ohta M, Tanaka F, Yamaguchi H, et al. The high expression of Fractalkine results in a better prognosis for colorectal cancer patients. Int J Oncol 2005 ; 26 : 41-7.
46. Rollins BJ, Sunday ME. Suppression of tumor formation in vivo by expression of the JE gene in malignant cells. Mol Cell Biol 1991 ; 11 : 3125-31.
47. Biragyn A, Kwak LW. B-cell malignancies as a model for cancer vaccines: from prototype protein to next generation genetic chemokine fusions. Immunol Rev 1999 ; 170 : 115-26.
48. Caux C, Ait-Yahia S, Chemin K, et al. Dendritic cell biology and regulation of dendritic cell trafficking by chemokines. Springer Semin Immunopathol 2000 ; 22 : 345-69.
49. Merad M, Fong L, Bogenberger J, et al. Differentiation of myeloid dendritic cells into CD8alpha-positive dendritic cells in vivo. Blood 2000 ; 96 : 1865-72.
50. Shedlock DJ, Weiner DB. DNA vaccination: antigen presentation and the induction of immunity. J Leukoc Biol 2000 ; 68 : 793-806.
51. Scheerlinck JY. Genetic adjuvants for DNA vaccines. Vaccine 2001 ; 19 : 2647-56.
52. Xin KQ, Lu Y, Hamajima K, et al. Immunization of RANTES expression plasmid with a DNA vaccine enhances HIV-1-specific immunity. Clin Immunol 1999 ; 92 : 90-6.
53. Sozzani S. Dendritic cell trafficking: more than just chemokines Cytokine Growth Factor Rev 2005 ; 16 : 581-92.
54. Moser B, Wolf M, Walz A, et al. Chemokines: multiple levels of leukocyte migration control. Trends Immunol 2004 ; 25 : 75-84.
55. O'Garra A, McEvoy LM, Zlotnik A. T-cell subsets: chemokine receptors guide the way Curr Biol 1998 ; 8 : R646-9.
56. Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 2003 ; 19 : 71-82.
57. + monocytes. J Exp Med 2003 ; 197 : 1701-7.
58. Maghazachi AA. Compartmentalization of human natural killer cells. Mol Immunol 2005 ; 42 : 523-9.